{"filing": {"accession": "0001178913-26-002862", "cik": "0001607962", "ticker": "LFWD", "company_name": "Lifeward Ltd.", "form_type": "10-Q", "filing_type": "10-Q", "filing_date": "2026-05-20", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326002862/0001178913-26-002862-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326002862/0001178913-26-002862-index.htm", "period_of_report": "2026-03-31"}, "html_url": "/api/filings/000117891326002862/stream", "exhibits": [{"exhibit_number": "31.1", "exhibit_type": "31", "description": "Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002.", "filename": "exhibit_31-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326002862/exhibit_31-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "31.2", "exhibit_type": "31", "description": "Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002.", "filename": "exhibit_31-2.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326002862/exhibit_31-2.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "32.1", "exhibit_type": "32", "description": "Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.", "filename": "exhibit_32-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326002862/exhibit_32-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "32.2", "exhibit_type": "32", "description": "Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.", "filename": "exhibit_32-2.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326002862/exhibit_32-2.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "2.1", "exhibit_type": "2", "description": "Share Purchase Agreement, dated January 12, 2026 among Lifeward, Ltd., Oramed Pharmaceuticals, Inc. and Oratech Pharma, Inc. (incorporated by reference to Exhibit 2.1 to the Company\u2019s Current Report on Form 8-K filed with the SEC on January 13, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_2-1.htm", "category": "other", "incorporated_by_reference": true}, {"exhibit_number": "2.2", "exhibit_type": "2", "description": "First Amendment to Share Purchase Agreement, dated March 25, 2026, by and among Lifeward Ltd., Oramed Pharmaceuticals, Inc. and Oratech Pharma Inc. (incorporated by reference to Exhibit 2.1 to the Company\u2019s Current Report on Form 8-K filed with the SEC on Maech 25, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/exhibit_2-1.htm", "category": "other", "incorporated_by_reference": true}, {"exhibit_number": "2.3", "exhibit_type": "2", "description": "Assignment and Assumption Agreement, dated March 25, 2026, by and between Oratech Pharma Inc. and Oratech Ltd. and acknowledged by Lifeward Ltd. (incorporated by reference to Exhibit 2.2 to the Company\u2019s Current Report on Form 8-K filed with the SEC on Maech 25, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/exhibit_2-2.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "4.1", "exhibit_type": "4", "description": "Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company\u2019s Current Report on Form 8-K filed with the SEC on January 13, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-1.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "4.2", "exhibit_type": "4", "description": "Form of Transaction Warrant (incorporated by reference to Exhibit 4.2 to the Company\u2019s Current Report on Form 8-K filed with the SEC on January 13, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-2.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "4.3", "exhibit_type": "4", "description": "Form of Senior Secured Convertible Note (incorporated by reference to Exhibit 4.3 to the Company\u2019s Current Report on Form 8-K filed with the SEC on January 13, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-3.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "4.4", "exhibit_type": "4", "description": "Form of Common Warrant (incorporated by reference to Exhibit 4.4 to the Company\u2019s Current Report on Form 8-K filed with the SEC on January 13, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-4.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "10.1", "exhibit_type": "10", "description": "Securities Purchase Agreement, dated January 12, 2026, by and among the Company and the investors thereto and Oramed Pharmaceuticals, Inc., as agent (incorporated by reference to Exhibit 10.2 to the Company\u2019s Current Report on Form 8-K filed with the SEC on January 13, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.2", "exhibit_type": "10", "description": "Form of Lock-up Agreement (incorporated by reference to Exhibit 10.1 to the Company\u2019s Current Report on Form 8-K filed with the SEC on January 13, 2026).", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_10-2.htm", "category": "contracts", "incorporated_by_reference": true}], "sections": [{"section_name": "part_1_item_1", "section_title": "FINANCIAL STATEMENTS", "start_position": 12048, "end_position": 84056}, {"section_name": "part_1_item_2", "section_title": "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS", "start_position": 84056, "end_position": 123250}, {"section_name": "part_1_item_3", "section_title": "QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK", "start_position": 123250, "end_position": 123570}, {"section_name": "part_1_item_4", "section_title": "CONTROLS AND PROCEDURES", "start_position": 123570, "end_position": 125513}, {"section_name": "part_2_item_1", "section_title": "LEGAL PROCEEDINGS", "start_position": 125513, "end_position": 125823}, {"section_name": "part_2_item_1a", "section_title": "RISK FACTORS", "start_position": 125823, "end_position": 125972}, {"section_name": "part_2_item_2", "section_title": "UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS", "start_position": 125972, "end_position": 126058}, {"section_name": "part_2_item_3", "section_title": "DEFAULTS UPON SENIOR SECURITIES", "start_position": 126058, "end_position": 126116}, {"section_name": "part_2_item_4", "section_title": "MINE SAFETY DISCLOSURES", "start_position": 126116, "end_position": 126167}, {"section_name": "part_2_item_5", "section_title": "OTHER INFORMATION", "start_position": 126167, "end_position": 126525}, {"section_name": "part_2_item_6", "section_title": "EXHIBITS", "start_position": 126525, "end_position": 130271}], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": "IsraelNot applicable"}, {"table_index": 1, "table_type": "text", "caption": null, "header_text": "2 Cabot Rd.,Hudson,MA01749"}, {"table_index": 2, "table_type": "text", "caption": null, "header_text": "Title of each classTrading SymbolName of each exchange on which registered"}, {"table_index": 3, "table_type": "text", "caption": null, "header_text": "Large accelerated filer\u2610Accelerated filer\u2610"}, {"table_index": 5, "table_type": "financial", "caption": null, "header_text": "Page No."}, {"table_index": 31, "table_type": "financial", "caption": null, "header_text": "March 31,December 31,"}, {"table_index": 34, "table_type": "financial", "caption": null, "header_text": "March 31,December 31,"}, {"table_index": 35, "table_type": "financial", "caption": null, "header_text": "Three Months EndedMarch 31,"}, {"table_index": 36, "table_type": "financial", "caption": null, "header_text": "Ordinary SharesAdditional paid-inTreasuryAccumulatedTotalshareholders\u2019"}, {"table_index": 37, "table_type": "financial", "caption": null, "header_text": "Three Months EndedMarch 31,"}, {"table_index": 47, "table_type": "financial", "caption": null, "header_text": "Fair value measurements as of"}, {"table_index": 48, "table_type": "text", "caption": null, "header_text": "March 31,2026December 31,2025"}, {"table_index": 49, "table_type": "text", "caption": null, "header_text": "March 31,2026December 31,2025"}, {"table_index": 50, "table_type": "text", "caption": null, "header_text": "Derivative liability"}, {"table_index": 51, "table_type": "text", "caption": null, "header_text": "Warrant liability"}, {"table_index": 54, "table_type": "financial", "caption": null, "header_text": "Three Months EndedMarch 31,"}, {"table_index": 55, "table_type": "financial", "caption": null, "header_text": "March 31,December 31,"}, {"table_index": 58, "table_type": "text", "caption": null, "header_text": "March 31,December 31,"}, {"table_index": 60, "table_type": "text", "caption": null, "header_text": "US Dollars in thousands"}, {"table_index": 70, "table_type": "text", "caption": null, "header_text": "March 31,December 31,"}, {"table_index": 73, "table_type": "text", "caption": null, "header_text": "AssetAllocated Cost"}, {"table_index": 85, "table_type": "text", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 86, "table_type": "text", "caption": null, "header_text": "NumberWeightedaverageexercisepriceWeightedaverageremainingcontractuallife (years)Aggregateintrinsicvalue (inthousands)"}, {"table_index": 87, "table_type": "text", "caption": null, "header_text": "Number ofsharesunderlyingoutstandingRSUsWeighted-averagegrant datefair value"}, {"table_index": 88, "table_type": "text", "caption": null, "header_text": "Range of exercise priceOptions and RSUsoutstanding as ofMarch 31, 2026Weightedaverageremainingcontractuallife (years) (1)Options outstanding andexercisable as ofMarch 31, 2026Weightedaverageremainingc"}, {"table_index": 92, "table_type": "financial", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 94, "table_type": "text", "caption": null, "header_text": "Issuance dateWarrantsoutstandingExercise priceper warrantWarrantsoutstandingandexercisableContractualterm"}, {"table_index": 112, "table_type": "financial", "caption": null, "header_text": "Three Months EndedMarch 31,"}, {"table_index": 114, "table_type": "financial", "caption": null, "header_text": "Three Months EndedMarch 31,"}, {"table_index": 115, "table_type": "financial", "caption": null, "header_text": "March 31,December 31,"}, {"table_index": 117, "table_type": "financial", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 125, "table_type": "financial", "caption": null, "header_text": "Three Months EndedMarch 31,"}, {"table_index": 126, "table_type": "financial", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 127, "table_type": "text", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 128, "table_type": "financial", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 129, "table_type": "financial", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 130, "table_type": "text", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 131, "table_type": "financial", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 132, "table_type": "financial", "caption": null, "header_text": "Three Months Ended March 31,"}, {"table_index": 133, "table_type": "financial", "caption": null, "header_text": "Three Months EndedMarch 31,"}, {"table_index": 134, "table_type": "text", "caption": null, "header_text": "Payments due by period (in dollars, in thousands)"}, {"table_index": 135, "table_type": "text", "caption": null, "header_text": "(1)Purchase obligations consist of non-cancelable purchase orders with suppliers for the manufacture of our ReWalk systems produced in-house and for AlterG Anti-Gravity systems manufactured by our con"}, {"table_index": 136, "table_type": "exhibit_index", "caption": null, "header_text": "ExhibitNumberDescription"}, {"table_index": 137, "table_type": "exhibit_index", "caption": null, "header_text": "*Furnished herewith."}, {"table_index": 138, "table_type": "text", "caption": null, "header_text": "Lifeward Ltd."}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 29}